Burning Mouth Syndrome

BioNTech and BMS Announce First Global Data for PD-L1xVEGF Bispecific in Small Cell Lung Cancer, Set Phase 3 Dose

1 week ago talkbio0Tagged BioNTech, BNT327, Burning Mouth Syndrome, Myers, Overall response rate, PD-L1, PD-L1xVEGF, Pharmacotherapy, pumitamig, Small cell carcinoma of lung, squibb, Vascular Endothelial Growth Factor A

BioNTech; Bristol Myers Squibb; BMS; PD-L1xVEGF bispecific; BNT327; pumitamig; small cell lung cancer; SCLC; phase 2 trial; phase 3 dose; overall response rate; VEGF-A; PD-L1; chemotherapy

Over 500 BMS jobs axed in latest round of NJ cuts

4 months ago talkbio0Tagged BMS, Burning Mouth Syndrome, campus, Drug Industry, employment reduction, Individual Adjustment, Lawrenceville, layoffs, Myers, New Jersey, squibb, WARN, Worker

Bristol Myers Squibb (BMS), Layoffs, New Jersey, Lawrenceville campus, Worker Adjustment and Retraining Notification (WARN), Pharmaceutical industry job cuts, Employment reduction

: BMS’ Opdivo plus Yervoy snags FDA nod as first-line treatment for certain colorectal cancer patients

5 months ago talkbio0Tagged Approved, Burning Mouth Syndrome, Colorectal Carcinoma, Combined, first-line, United States Food and Drug Administration, Yervoy

United States Food and Drug Administration, Approved, Burning Mouth Syndrome, Colorectal Carcinoma, Yervoy, first-line, Combined

BMS snaps up Abecma partner 2seventy bio in $286M all-cash deal

6 months ago talkbio0Tagged Abecma, BMS, Burning Mouth Syndrome

Burning Mouth Syndrome, Abecma, BMS, Abecma

BMS’ CAR-T Therapy Shows Promising Results in Treating Lupus, Achieving Sustained Responses in Phase 1 Trial

10 months ago talkbio0Tagged Autoimmune Diseases, Automobiles, BMS, Burning Mouth Syndrome, Cell Therapy, Clinical Trials, Lupus Erythematosus, Systemic, Lupus treatment, squibb, T therapy

CAR T therapy, Lupus treatment, Bristol Myers Squibb (BMS), Systemic lupus erythematosus (SLE), Autoimmune diseases, Cell therapy, Clinical trials

Bristol Myers Squibb Invests $110 Million in T-Cell Therapy Pact with Prime Medicine

12 months ago talkbio0Tagged biotech, BMS, Burning Mouth Syndrome, ex vivo, Investments, Myers, pharmaceutical partnerships, Prime Medicine, squibb, T-cell therapy

Bristol Myers Squibb (BMS), Prime Medicine, T-cell therapy, Ex vivo therapies, Biotech investment, Pharmaceutical partnerships

Federal Judge Dismisses $6.4 Billion Lawsuit Against Bristol Myers Squibb Over Celgene Acquisition

12 months ago talkbio0Tagged BMS, Burning Mouth Syndrome, Celgene Acquisition, CVR, Drug Industry, federal, Judge, Legal Dispute, Myers, squibb

Bristol Myers Squibb (BMS), Celgene Acquisition, $6.4 Billion Lawsuit, Contingent Value Rights (CVR), Federal Judge Ruling, Pharmaceutical Industry, Legal Dispute

Prime Medicine Partners with Bristol Myers Squibb in $3.5B Cell Therapy Deal, Narrows Pipeline Focus

12 months ago talkbio0Tagged BMS, Burning Mouth Syndrome, Cell Therapy, Edit, ex vivo, Gene Modification, Ifosfamide/Methotrexate/Procarbazine protocol, PASSIGE, pipeline, Prime Medicine, Reprioritization, squibb, strategic collaboration, Technology

Prime Medicine, Bristol Myers Squibb (BMS), Cell Therapy, Gene Editing, Prime Editing, PASSIGE Technology, Ex Vivo T-Cell Therapies, Pipeline Reprioritization, Strategic Collaboration